<DOC>
	<DOCNO>NCT01752582</DOCNO>
	<brief_summary>The objective study comparative evaluation BuMA stent EXCEL stent term extent neointima formation 3 month implantation use OCT . This prospective , single center , randomize , open-label , non-inferiority study , enroll total 70 patient Fuwai Hospital.All patient randomly assign undergoing implantation BuMA stent EXCEL stent ( 1:1 ratio ) . If non-inferiority met , superiority test plan .</brief_summary>
	<brief_title>BuMA OCT Study ( A Comparative Evaluation Extent Neointima Formation 3 Months After Implantation Using OCT )</brief_title>
	<detailed_description>About 70 patient clinical evidence ischemic heart disease / positive functional study document stable angina pectoris ( Canadian cardiovascular society classification ( CCS ) 1 , 2 , 3 4 ) , document silent ischemia de-novo , native , previously unstented vessel Fuwai Hospital , randomly assign undergoing implantation BuMA stent EXCEL stent ( 1:1 ratio ) . All patient receive 6 month dual antiplatelet therapy follow ( outpatient clinic ) 2 year . The follow-up visit conduct 3 month ( include angiographic/OCT investigation ) , 6 month , 1 2 year post percutaneous coronary intervention ( PCI ) , order observe Primary Endpoint Secondary Endpoints .</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Angina Pectoris</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Angina , Unstable</mesh_term>
	<mesh_term>Angina , Stable</mesh_term>
	<mesh_term>Neointima</mesh_term>
	<mesh_term>Chlorhexidine</mesh_term>
	<mesh_term>Chlorhexidine gluconate</mesh_term>
	<criteria>18 85 year . Evidence myocardial ischemia without raise troponin ( e.g . stable unstable angina , silent ischemia demonstrate positive territorial functional study ) . The patient plan intervention four de novo lesion , different epicardial vessel . Lesion ( ) must visually estimate diameter stenosis â‰¥50 % &lt; 100 % . Reference Vessel Diameter ( RVD ) must 2.54.0 mm Written inform consent . The patient patient 's physician agree followup visit include angiographic followup OCT control 3 month . Evidence ongoing acute myocardial infarction ECG prior procedure . Left ventricular ejection fraction ( LVEF ) &lt; 30 % . Documented suspect liver disease ( include laboratory evidence hepatitis ) . Known renal insufficiency ( e.g . estimate glomerular filtration rate ( eGFR ) &lt; 60 ml/kg/m2 serum creatinine level &gt; 2.5 mg/dL , subject dialysis ) . History bleed diathesis coagulopathy . The patient recipient heart transplant . Known hypersensitivity contraindication aspirin , heparin bivalirudin , antiplatelet medication specify use study ( clopidogrel ticlopidine ) , sirolimus stainless steel . Other medical illness ( e.g . cancer , neurological deficiency ) know history substance abuse ( alcohol etc . ) per physician judgment may cause noncompliance protocol confound data interpretation associate limited life expectancy . Pregnant breastfeed woman woman fertile period take adequate contraceptive OCT exclusion criterion Severe tortuous , calcify angulated coronary anatomy study vessel opinion investigator would result suboptimal image excessive risk complication placement OCT catheter Total occlusion thrombolysis myocardial infarction ( TIMI ) flow 0 , prior wire crossing .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>BuMA</keyword>
	<keyword>EXCEL</keyword>
	<keyword>OCT</keyword>
	<keyword>stent</keyword>
	<keyword>neointima formation</keyword>
</DOC>